United States Liquid Biopsy Market Size & Forecast 2025–2034

The United States Liquid Biopsy Market is expected to witness remarkable growth in the coming years, driven by the increasing demand for non-invasive cancer diagnostic technologies. Liquid biopsy is rapidly emerging as a revolutionary diagnostic tool because it enables doctors to detect cancer through simple blood tests instead of traditional surgical procedures.

According to Renub Research, the United States Liquid Biopsy Market is projected to reach US$ 4.86 Billion by 2034, rising from US$ 1.39 Billion in 2025, growing at a compound annual growth rate (CAGR) of 14.93% during 2026–2034. The expansion of precision medicine, advancements in genomic technologies, and the rising burden of cancer are some of the key factors fueling this market.

Download Sample Report

With healthcare systems increasingly focusing on early detection and personalized treatment strategies, liquid biopsy is expected to become a cornerstone of modern oncology diagnostics.

United States Liquid Biopsy Market Outlook

Liquid biopsy is a medical diagnostic test used to identify disease-related markers such as tumor cells, circulating tumor DNA (ctDNA), and other molecular biomarkers present in bodily fluids—most commonly blood. Unlike conventional tissue biopsy, which requires invasive surgical procedures to obtain tissue samples, liquid biopsy only requires a small blood sample.

This minimally invasive technique offers several advantages, including faster diagnosis, improved patient comfort, and the ability to monitor disease progression repeatedly without surgical risks.

In the United States, liquid biopsy is gaining significant traction because of its ability to detect cancer at early stages, monitor treatment responses, and identify genetic mutations that help guide targeted therapies. Physicians and healthcare providers increasingly prefer this technology due to its convenience, accuracy, and safety.

Additionally, the strong healthcare infrastructure in the United States, along with substantial investments in biotechnology and genomic research, is further accelerating the adoption of liquid biopsy technologies.

Growth Drivers of the United States Liquid Biopsy Market

Increasing Prevalence of Cancer and Rising Demand for Early Detection

One of the primary drivers of the liquid biopsy market in the United States is the rising incidence of cancer. Cancer remains one of the leading causes of death across the country, creating an urgent need for improved diagnostic methods that can detect the disease earlier.

In 2025, the United States is expected to record approximately 2,041,910 new cancer cases and 618,120 cancer-related deaths. These alarming numbers highlight the growing need for advanced diagnostic technologies capable of identifying cancer at its earliest stages.

Liquid biopsy addresses this challenge by allowing doctors to detect cancer through circulating tumor DNA and other biomarkers found in blood samples. Early detection significantly increases the chances of successful treatment and improves overall patient survival rates.

Moreover, liquid biopsy enables continuous monitoring of cancer progression and recurrence. This capability allows physicians to track how patients respond to treatment and adjust therapy strategies accordingly.

For example, in 2024, approximately 18.4 million adults were eligible for lung cancer screening, yet only about 15% underwent screening, demonstrating the significant potential for improved diagnostic adoption. As awareness about early cancer detection grows, the demand for liquid biopsy testing is expected to increase substantially across the United States.

Advancements in Genomic and Molecular Diagnostic Technologies

Technological innovation is another major factor fueling the growth of the liquid biopsy market. Advances in genomic sequencing, molecular diagnostics, and biomarker detection have significantly improved the accuracy and sensitivity of liquid biopsy tests.

Technologies such as Next-Generation Sequencing (NGS) allow researchers and clinicians to analyze genetic mutations associated with cancer more effectively. These technological advancements enable the identification of disease markers even when they are present in extremely small quantities.

Artificial intelligence and advanced bioinformatics tools are also enhancing the analytical capabilities of liquid biopsy tests. These technologies help identify complex genetic patterns and improve diagnostic precision.

The United States hosts one of the most advanced biotechnology ecosystems in the world, with numerous research institutions and companies working on innovative diagnostic solutions.

For instance, in December 2025, Roche launched the cobas 6800/8800 systems version 2.0 in the United States after receiving FDA 510(k) clearance. These upgraded molecular diagnostic platforms improve laboratory efficiency through optimized resource allocation, reduced downtime, and increased testing capacity.

Such technological developments continue to strengthen the reliability and scalability of liquid biopsy diagnostics, thereby supporting market growth.

Growing Adoption of Personalized Medicine and Targeted Therapies

Another important factor driving the United States liquid biopsy market is the increasing adoption of personalized medicine and targeted therapies.

Personalized medicine focuses on tailoring medical treatment based on the genetic profile of an individual patient. Liquid biopsy plays a crucial role in this approach by identifying genetic mutations and biomarkers that guide treatment decisions.

Through molecular analysis, doctors can determine which therapies are most effective for specific patients, improving treatment outcomes while minimizing side effects.

Pharmaceutical companies and healthcare providers are increasingly using liquid biopsy tests to identify patients who may benefit from targeted therapies. This trend is strengthening the role of liquid biopsy in precision oncology.

For example, in April 2025, Labcorp expanded its precision oncology portfolio by introducing Labcorp Plasma Detect, designed to assess recurrence risk in Stage III colon cancer patients. The company also launched PGDx elio plasma focus Dx, the first FDA-authorized kitted pan-solid tumor liquid biopsy test capable of identifying patients who may benefit from targeted cancer therapies.

As personalized medicine continues to evolve, liquid biopsy technologies will become even more critical in supporting advanced treatment strategies.

Challenges of the United States Liquid Biopsy Market

High Cost of Testing and Limited Insurance Coverage

Despite its advantages, liquid biopsy testing can be expensive due to the advanced technologies involved in genomic sequencing and biomarker analysis.

The cost of testing may limit accessibility for certain patient groups, especially those without comprehensive insurance coverage. While the long-term clinical benefits of early detection are significant, the upfront cost can discourage widespread adoption.

Additionally, reimbursement policies for liquid biopsy testing are still evolving in the United States. Many insurance providers are still assessing coverage policies for these diagnostic tests.

However, increasing competition among biotechnology companies and continuous technological innovation are expected to gradually reduce testing costs, making liquid biopsy more accessible to a broader population.

Regulatory and Clinical Validation Challenges

Another major challenge for the liquid biopsy market is the strict regulatory approval process required to ensure diagnostic accuracy and reliability.

New diagnostic tests must undergo rigorous clinical validation before receiving regulatory approval. These processes can be time-consuming and expensive, slowing the development and commercialization of innovative products.

Healthcare providers also require strong clinical evidence before adopting new diagnostic tools. Inconsistent test results and the lack of standardized testing protocols can further complicate regulatory approval.

Manufacturers must therefore invest heavily in research, clinical trials, and regulatory compliance to ensure their products meet required standards.

Despite these challenges, continued research and collaboration between biotechnology companies, healthcare providers, and regulatory agencies are expected to improve the reliability and adoption of liquid biopsy technologies.

Key Market Segments in the United States Liquid Biopsy Industry

Lung Liquid Biopsy Market

The lung liquid biopsy segment is expanding rapidly due to the increasing incidence of lung cancer in the United States. Early detection plays a crucial role in improving treatment outcomes, making liquid biopsy a valuable diagnostic tool.

This technology allows doctors to detect genetic mutations and tumor markers using blood samples, eliminating the need for invasive tissue biopsies. Liquid biopsy is particularly beneficial for lung cancer patients who cannot undergo surgical procedures.

Furthermore, physicians can use this diagnostic approach to monitor disease progression and evaluate the effectiveness of targeted therapies.

Liquid Biopsy Kits & Reagents Market

Kits and reagents are essential components of liquid biopsy testing. These products enable laboratories to extract, process, and analyze biomarkers such as circulating tumor DNA and circulating tumor cells.

The increasing demand for diagnostic testing is driving growth in this segment. Biotechnology firms and diagnostic laboratories rely on high-quality reagents to ensure accurate and reliable test results.

Continuous innovations in molecular diagnostics are improving the efficiency and performance of these products, further supporting market expansion.

Liquid Biopsy Patient Monitoring Market

Liquid biopsy is becoming an important tool for continuous cancer monitoring. It allows healthcare providers to track disease progression, detect recurrence, and evaluate patient responses to treatment.

By providing real-time insights into tumor behavior, liquid biopsy enables doctors to adjust treatment strategies more effectively.

As personalized medicine and targeted therapies become more widespread, the demand for patient monitoring solutions is expected to increase significantly.

Circulating Tumor DNA (ctDNA) Market

Circulating tumor DNA is one of the most widely studied biomarkers in liquid biopsy diagnostics. These DNA fragments carry important genetic information about tumors and their mutations.

ctDNA analysis helps detect cancer at early stages, monitor disease progression, and guide targeted treatment strategies.

Advances in next-generation sequencing and molecular diagnostics are enhancing the detection accuracy of ctDNA, making it a critical component of precision medicine.

Hospitals as Key End-Users

Hospitals represent one of the largest end-user segments in the liquid biopsy market. They play a central role in cancer diagnosis, treatment, and patient management.

Many hospitals are integrating liquid biopsy tests into oncology workflows because the technology provides faster results and improves patient comfort.

Collaborations between hospitals, research institutions, and biotechnology companies are also accelerating innovation in liquid biopsy technologies.

Regional Insights: Key State Markets

Several states are emerging as major hubs for liquid biopsy adoption in the United States.

California leads the market due to its strong biotechnology ecosystem and advanced healthcare infrastructure. The state hosts numerous biotech companies and research centers working on genomic medicine and precision diagnostics.

New York is another important market, supported by world-class hospitals, research institutions, and cancer treatment facilities. The growing demand for advanced diagnostic technologies is driving adoption across the state.

New Jersey benefits from a strong pharmaceutical and biotechnology industry presence. Partnerships between biotech companies and healthcare providers are accelerating innovation in liquid biopsy technologies.

Meanwhile, Washington State is experiencing steady growth due to rising investments in healthcare infrastructure and increasing awareness of precision medicine.

Competitive Landscape

The United States liquid biopsy market is highly competitive and includes several leading biotechnology and diagnostics companies focusing on research, innovation, and product development.

Key companies operating in the market include:

Thermo Fisher Scientific Inc.

Roche Diagnostics

Bio-Rad Laboratories Inc.

Biocept Inc.

Biocartis

Myriad Genetics Inc.

Exact Sciences (Genomic Health)

NeoGenomics Laboratories

Quest Diagnostics Inc.

These companies are investing heavily in research and development to improve diagnostic accuracy, expand testing capabilities, and strengthen their positions in the growing precision medicine market.

Final Thoughts

Liquid biopsy is transforming cancer diagnostics by offering a faster, safer, and non-invasive alternative to traditional tissue biopsy. As cancer rates continue to rise and healthcare systems focus more on early detection and personalized treatment, liquid biopsy technologies are expected to play a critical role in the future of oncology.

The United States, with its advanced biotechnology ecosystem and strong healthcare infrastructure, is positioned to lead global innovation in this field.

With continued technological advancements, supportive research initiatives, and increasing awareness of precision medicine, the United States Liquid Biopsy Market is set for significant expansion through 2034—bringing new opportunities for improved cancer diagnosis, treatment, and patient outcomes.